Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk.
Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk. JAMA Netw Open. 2024 Nov 04; 7(11):e2446336.
PMID: 39565623
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. J Natl Compr Canc Netw. 2024 Nov; 22(9):582-592.
PMID: 39536465
Studying Outcomes after Steroid-Sparing Immunosuppressive Agent vs. Steroid-Only Treatment for Immune-Related Adverse Events in Non-Small-Cell Lung Cancer (NSCLC) and Melanoma: A Retrospective Case-Control Study.
Studying Outcomes after Steroid-Sparing Immunosuppressive Agent vs. Steroid-Only Treatment for Immune-Related Adverse Events in Non-Small-Cell Lung Cancer (NSCLC) and Melanoma: A Retrospective Case-Control Study. Cancers (Basel). 2024 May 16; 16(10).
PMID: 38791970
Current and future advances in practice: aromatase inhibitor-induced arthralgia.
Current and future advances in practice: aromatase inhibitor-induced arthralgia. Rheumatol Adv Pract. 2024; 8(2):rkae024.
PMID: 38601139
Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis.
Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis. Rheum Dis Clin North Am. 2024 05; 50(2):161-179.
PMID: 38670719
Immune Checkpoint Inhibitors and Lupus Erythematosus.
Immune Checkpoint Inhibitors and Lupus Erythematosus. Pharmaceuticals (Basel). 2024 Feb 15; 17(2).
PMID: 38399467
Immunotherapy Toxicity Management in Clinical Practice: Building the Clinical Infrastructure for Immune-related Adverse Event Evaluation and Care.
Immunotherapy Toxicity Management in Clinical Practice: Building the Clinical Infrastructure for Immune-related Adverse Event Evaluation and Care. Rheum Dis Clin North Am. 2024 05; 50(2):229-239.
PMID: 38670722
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases. Oncoimmunology. 2023; 12(1):2261264.
PMID: 38126033
JAK inhibitors and black box warnings: what is the future for JAK inhibitors?
JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol. 2023 Jul-Dec; 19(11):1385-1397.
PMID: 37596779
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors.
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors. Drug Saf. 2023 11; 46(11):1049-1071.
PMID: 37490213